PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
16 Ottobre 2023 - 10:05PM
PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced it
will report financial results for the third quarter of 2023 after
market close on Wednesday, November 1, 2023. The Company’s
management will host a corresponding conference call beginning at
4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/cycnvr77
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BIc491d3ec87c645f08218c0c5909923e2
Live audio of the webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com. Each webcast will be available
for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
Grafico Azioni PROCEPT BioRobotics (NASDAQ:PRCT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni PROCEPT BioRobotics (NASDAQ:PRCT)
Storico
Da Mag 2023 a Mag 2024